Recent Headlines
OsoBio Appoints David M. Lee Vice President of Quality
OsoBio has named David M. Lee vice president of quality. Lee is responsible for overseeing all quality-related functions to ensure the company’s continued compliance with Current Good Manufacturing Practices (cGMP), including quality systems, quality control and manufacturing quality... - May 10, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
Herpes Solution Provider, Viradux Research Announces JV Partnership
A new development in the war against genital and oral herpes. - April 26, 2013 - viradux
YaxinBio Launches 2 New Products: Enterokinase and V8 Protease
Shanghai Yaxin Biotechnology Co., Ltd. offers two new recombinant proteins. Recombinant Bovine enterokinase, also known as enteropeptidase, is a specific protease used for tag removal, while V8 Protease (Endoproteinase GluC) is highly important for protein structure and sequence... - April 23, 2013 - Shanghai Yaxin Biotechnology Co. Ltd.
Eye Doctor Finds Impressive Vision Improvements from Stem Cell Treatment Reports MD Stem Cells
Post-operative visual acuity significantly improved following stem cell treatment for Macular Degeneration according to an independent Optometrist in California. - April 12, 2013 - MD Stem Cells
Virtual Model of Novel Cancer Target Developed
Plebiotic and Pharmacellion Complete Research Project on an in silico Molecular Modelling and Molecular Dynamics Model of Na K ATPase. - April 12, 2013 - Ventac Partners
Houston Bariatric Practice Hits Surgery Milestone: 100th SPIDER ® Sleeve
Gastric sleeve weight-loss surgery patients report satisfaction with lack of visible scars, recovery and comfort. - April 10, 2013 - TransEnterix
MD Stem Cells - Macular Degeneration Patient Continues to Improve Following Stem Cell Treatments
Married for 72 years, patient’s husband confirms positive visual results are continuing for his wife following stem cell treatment for AMD. - March 23, 2013 - MD Stem Cells
SFL Appoints Advisory Board
SFL announces details of its Advisory Board. - March 22, 2013 - SFL Regulatory Affairs & Scientific Communication Ltd
F2G Ltd Appoints Ian Nicholson as Chief Executive Officer
F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors. - March 20, 2013 - F2G Ltd
Arbovax Completes Successful Pre-Clinical Trial of Tetravalent Dengue Vaccine
Successful Pre-Clinical Tests Support Vaccine Platform, New Injection Protocol - March 19, 2013 - Arbovax Inc
Promoters for Improved Protein & Biopharmaceutics Production in Mammalian Cells
Synpromics Ltd, the synthetic promoter company, announces the award by the Technology Strategy Board, the UK’s innovation agency, of an over £240,000 grant under the TSB’s Synthetic Biology initiative to a consortium led by Synpromics and also including Genabler Ltd and the University of Edinburgh’s SynthSys Centre for Synthetic and Systems Biology. - March 09, 2013 - Synpromics Ltd
MMS Set to Expand Disclosure Services with Registry Reporting Software TrialAssure™
MMS Holdings Inc. today announced that it has successfully executed disclosure management services for several clients and is poised to make strides in this area with its proprietary software, TrialAssure™. TrialAssure™ is a workflow management system that supports the reporting of... - March 02, 2013 - MMS Holdings Inc.
SFL Experts to Present and Chair Sessions at the 2013 DIA Annual EuroMeeting
SFL team showcase expertise in Regulatory Affairs, Public Affairs, Legal Services and Medical Communications at DIA EuroMeeting in Amsterdam. - March 01, 2013 - SFL Regulatory Affairs & Scientific Communication Ltd
Ohio State and Biosortia Pharmaceuticals to Join Forces to Discover Anti-Cancer Compounds
The Ohio State University has signed an agreement with Biosortia Pharmaceuticals of Dublin, Ohio to discover new biologically active natural products with potential anti-cancer activity. Potential candidate compounds discovered during the Biosortia-sponsored research project will primarily be tested against human colon cancer assays. The ultimate goal is to obtain lead compounds that can be licensed to and developed by pharmaceutical companies through Biosortia’s pharmaceutical relationships. - February 28, 2013 - Biosortia Pharmaceuticals
OsoBio President to Join Injectable Trends Discussion at DCAT Week
OsoBio President Milton Boyer and other experts will examine industry's shortages. - February 22, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
MD Stem Cells: Very Elderly Benefit from Stem Cells for Macular Degeneration
92 year old shows rapid vision results with stem cells. Age is not a barrier to visual improvement following stem cell treatment reports MD Stem Cells. - February 21, 2013 - MD Stem Cells
Cambridge Healthtech Institute & Bio-IT World Announces Program for Its 13th Annual Structure-Based Drug Design Conference, June 19-21, 2013, Boston, MA
Featuring Keynote from Aileron Therapeutics’ Tomi Sawyer - February 16, 2013 - Cambridge Healthtech Institute
MD Stem Cells Begins Intravitreal Stem Cell Treatments for Severe Visual Loss
New Intravitreal Stem Cell Injection Approach to Improve Vision is Now Available through MD Stem Cells. - February 15, 2013 - MD Stem Cells
Xeno Diagnostics, LLC Receives Award for Laboratory Excellence
Xeno Diagnostics, LLC Recognized for Quality Laboratory Services - February 15, 2013 - Xeno Diagnostics, LLC
Greenwerkz Releases R4 Ultra-High CBD, Non-Psychoactive Strain as "Open Source"
Greenwerkz' high CBD/low THC strain genetics to become available to patients and medical marijuana centers (MMCs) in Colorado, free of charge. - February 14, 2013 - Greenwerkz
SFL’s Managing Director Invited to Speak at MEDTEC Europe Event in Stuttgart, Germany
SFL is pleased to announce that Shayesteh Fürst-Ladani, SFL’s Managing Director, has been invited to give a presentation on the classification and regulation of drug/device combinations at the MEDTEC Europe event to be held in Stuttgart, Germany from 26 to 28 February 2013. - February 13, 2013 - SFL Regulatory Affairs & Scientific Communication Ltd
AnaSpec Introduces Two New SensoLyte® Cathepsin L Assay Kits
AnaSpec is pleased to announce the release of two new SensoLyte® assay kits for the measurement of Cathepsin L activity – the SensoLyte® 520 and Rh110 Cathepsin L Assay Kits. The former utilizes a FRET (fluorescent resonance energy transfer)-based peptide substrate and the latter, a... - February 09, 2013 - AnaSpec, EGT Group
MoBiTec GmbH, Germany, is Offering Glycan Arrays for Multiple Analysis of Glycan-Related Interactions
MoBiTec Germany, in cooperation with the Japanese company Sumitomo Bakelite Co. Ltd., is offering to its European customers Glycan Arrays that are useful for studies on the interaction of microorganisms, analysis of glycan-binding proteins, autoantibodies and more. - February 09, 2013 - MoBiTec GmbH
BANG® – as Official Energy Drink of NHL Florida Panthers & BB&T Center
It was just announced that VPX’s BANG® will be named official energy drink of the NHL Florida Panthers and the BB&T Center, formerly known as the Bank Atlantic Center. - February 07, 2013 - VIRUN
Billion Cell Milestone Reached in Stem Cell Treatment
MD Stem Cells Reports Almost Two Billion Cells Used in Eye Stem Cell Treatment in Florida. - February 07, 2013 - MD Stem Cells
Molecular Medicine Tri-Conference 2013 - Complimentary Hall Passes Now Available
Gain access to solutions and connections for Diagnostics, Informatics, Clinical, Cancer, Therapeutics, Sequencing, Genomics and Medicine and more at Cambridge Healthtech Institute's 20th Annual Molecular Medicine Tri-Conference (Triconference.com/hallpass) - February 02, 2013 - Cambridge Healthtech Institute
CHI Releases List of Delegates for Targeting Cancer Stem Cells Symposium in San Francisco, CA
To be held on February 11-12, 2013 at the Moscone North Convention Center, San Francisco, CA - Part of the Molecular Med TRI-CON 2013. - January 26, 2013 - Cambridge Healthtech Institute
Tampa Bay Surgeons Offer Virtually Scarless Weight-Loss Procedure
Sun Coast Bariatrics is using the SPIDER® Surgical System to perform single-incision sleeve gastrectomy. - January 26, 2013 - TransEnterix
Optic Nerve Vision Loss Reversed with New Stem Cell Treatment
MD Stem Cells helps nearly blind car accident victim regain her sight in Florida and see her mother’s face again- other neurologic benefits reported as well. - January 24, 2013 - MD Stem Cells
Novel Health Strategies Announces Publication of Annual and Recurring Strategy Overview on Emerging Life Sciences Market Trends
Novel Health Strategies Study Shows Oncology, Diabetes and Auto-Immune Indications Driving Growth of the Biotech Sector; More Products Facing Market Access Challenges. - January 24, 2013 - Novel Health Strategies
MD Stem Cells Improves Myopic Macular Degeneration with New Stem Cell Treatment
MD Stem Cells helps Australian patient travel half way around the world for stem cell treatment in Florida to achieve significant improvement in vision. - January 14, 2013 - MD Stem Cells
AnaSpec Offers a Wide Selection of SYBR® qPCR MasterMixes and Core Kits
AnaSpec, EGT Group offers a wide selection of SYBR® Green-based MasterMixes and Core Kits for almost any thermocycler available in the industry. - January 12, 2013 - AnaSpec, EGT Group
MoBiTec GmbH, Germany, is Offering TurboLigation™ Kit, Enabling Quick Ligation of DNA Molecules in Just 5 Minutes at a Bargain Price
Combining heterologous DNA molecules is a key process in most traditional molecular cloning experiments. This process, facilitated by the enzyme DNA ligase, usually takes about 16 hours. With the TurboLigation™ Kit the reaction time is greatly reduced down to just 5 minutes without compromising the efficiency. - December 22, 2012 - MoBiTec GmbH
2012 - An Award-Winning Year for SFL
This year, SFL’s multifunctional expertise has been independently recognised through two important business awards. In July, Shayesteh Fürst-Ladani, Managing Director of the company, received the Open University Business School’s Alumni Award Outstanding Contribution to an... - December 19, 2012 - SFL Regulatory Affairs & Scientific Communication Ltd
MoBiTec GmbH, Germany, Introduces New Multiplex Secretion Gene Expression System for Bacillus subtilis
Bacillus subtilis has become an increasingly popular host for recombinant protein expression. With its ability to secrete protein directly into culture media, and designation by the U.S. Food and Drug Administration as an organism that is Generally Regarded As Safe (GRAS), the majority of industrially-produced enzymes are expressed in Bacillus species such as B. subtilis. To address this, MoBiTec introduces the new Bacillus subtilis Multiplex Secretion Expression System. - December 13, 2012 - MoBiTec GmbH
Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research
AnaSpec has developed a series of highly sensitive assay kits for the detection of the activities of HDAC (Histone Deacetylase), SIRT (Sirtuin) 1 & 2 or HAT (Histone Acetyltransferases). - December 07, 2012 - AnaSpec, EGT Group
AnaSpec Introduces SensoLyte® ThT Aβ42 & Aβ40 Aggregation Kits
AnaSpec has developed the SensoLyte® ThT Aß40 and Aß42 Aggregation kits to provide a convenient and standard method for measurement of Aß40 and Aß42 aggregation, respectively. - December 06, 2012 - AnaSpec, EGT Group
VPX Sports® Introduces BANG® – an Intelligent Beverage Design Aimed to Change Typical “Energy Drink” Perception
The beverage innovators at VPX® have re-defined the “energy drink” category by introducing BANG® -- a novel, great-tasting 16 ounce carbonated beverage formulated to fuel the brain and body. “BANG® is not your typical high sugar, health robbing beverage,” rather, BANG® consists of several patent-pending compounds and patented compositions intelligently designed to deliver results “…without the sugar-induced metabolic mayhem and crash.” -Jack Owoc, Chief Executive & Science Officer for VPX Sports - November 30, 2012 - VIRUN
SFL Selected as Finalist in the British-Swiss Business Awards
SFL Regulatory Affairs & Scientific Communication Ltd (SFL) is proud to announce that the company has been selected as a finalist in the second annual British-Swiss Business Awards. - October 13, 2012 - SFL Regulatory Affairs & Scientific Communication Ltd
Results of Type C Guidance Meeting with Food & Drug Administration (FDA) of ZYDIS® ODT Fluoxetine in the Treatment of Repetitive Behaviors in Autism
Autism Therapeutics LLC ("Autism Therapeutics") announced today that the Type C Guidance Meeting with FDA to discuss the ZYDIS® ODT Fluoxetine / Autism program has taken place. The FDA and Autism Therapeutics discussed the completion of the Phase III development of the program... - October 09, 2012 - Autism Therapeutics LLC
OsoBio Appoints Alan P. Heim as Vice President of Human Resources
OSO BioPharmaceuticals Manufacturing, LLC, has appointed Alan P. Heim as vice president of human resources. In his capacity, Heim administers all policies and programs that affect personnel at OsoBio, including issues such as organizational planning; recruitment, hiring and training; employee... - October 05, 2012 - OSO BioPharmaceuticals Manufacturing, LLC
SignaBlok Awarded NCI Grant to Test New Approach to Lung Cancer Treatment
SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer. - October 03, 2012 - SignaBlok, Inc.
MoBiTec to Exhibit at the 16th Joint Meeting of the Signal Transduction Society (STS) 2012 in Weimar, Germany, to Represent Echelon Biosciences Inc. And Bellbrook Labs
Tools for Lipid Research from Echelon Biosciences Inc., and BellBrook Labs' Transcreener HTS Assays - a Universal, High Throughput Screening Platform for Enzymes based on direct Detection of Nucleotide Enzyme Products with Far Red FI, FP and TR-FRET Readouts - are some of the Highlights MoBiTec is going to Present at this Years STS Meeting in Weimar, Germany. - September 23, 2012 - MoBiTec GmbH
SFL’s Managing Director Invited to Speak at World Medtech Forum
Shayesteh Fürst-Ladani, Managing Director of the SFL will speak on European Day at the World Medtech Forum in Lucerne, Switzerland. - September 22, 2012 - SFL Regulatory Affairs & Scientific Communication Ltd
New Product Launch - Green Leaf Labs
Before the end of 2012 new N-(2-Hydroxyethyl) hexadecanamide products will be available worldwide with updated product specifications. - September 12, 2012 - Green Leaf Labs
Breakout Discussion Groups Announced at CHI's Immunogenicity Summit 2012 in Bethesda, MD, Oct. 10-12
Delegates now have the option to choose from 10 moderated breakout discussion groups at this industry leading event facilitated by FDA and industry and academic experts. - September 11, 2012 - Cambridge Healthtech Institute
SFL’s Managing Director and Head of UK Office to Speak at DIA Combination Products Workshop in Basel, Switzerland
SFL’s team to provide delegates with an understanding of the regulatory framework for drug/device combinations and drug/companion diagnostics in the EU. - September 08, 2012 - SFL Regulatory Affairs & Scientific Communication Ltd
MoBiTec GmbH, Germany, Closes Distribution Agreement with VIDIA Ltd., Czech Republic, to Distribute ELISA Kits for Human Medicine and for Environmental Monitoring
VIDIA Ltd. is a private Czech biotechnological company with its own research and development department that closely cooperates with The Academy of Sciences of the Czech Republic, hospitals and universities. VIDIA is producer of diagnostic kits for human medicine and for environmental monitoring. MoBiTec distributes products from several international companies in Germany and across the world, next to its own product line. - September 07, 2012 - MoBiTec GmbH
VIRUN® Receives Eighth Notice-of-Allowance for Patent Applications and Introduces New “Space” Within Industry
After only a short while, VIRUN has obtained numerous Notice-of-Allowances and several patent grants for its nano-encapsulation technologies that allow non polar compounds, such as CoQ10 and Omega-3 EPA DHA, to dissolve clearer and shelf stable into foods and beverages. With this increase in patent proliferation, VIRUN introduces the NUTRA-BIOsciences™ platform to accelerate the expansion and exclusivity of new and added-value food/beverage products. - August 30, 2012 - VIRUN
AnaSpec Introduces SensoLyte® Enterokinase Assay Kits
AnaSpec, EGT Group is pleased to announce the release of two assay kits for quantitating enterokinase enzymatic activity – the SensoLyte® 520 and SensoLyte® Rh110 Enterokinase Activity Assay Kits. The former is a FRET (fluorescence resonance energy transfer)-based assay employing a... - August 30, 2012 - AnaSpec, EGT Group